May. 12 at 11:05 AM
$ARVN &
$PFE to receive
$85 million in upfront and transition payments with potential for additional
$320 million in development, regulatory, and commercial milestones and tiered royalites on net sales. Upfront cash "to be distributed evenly between Arvinas and Pfizer."
$RIGL will be responsible for the launch and commercialization of VEPPANU in the U.S. and will own global rights with the ability to sublicense to potential partners to further develop and commercialize VEPPANU outside of the U.S.
